|
Market Closed -
NYSE
21:00:00 03/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.620 USD | +1.16% |
|
+0.38% | +45.56% |
| 08-12 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Stock exchange
Quotes 5-day view: Protalix BioTherapeutics, Inc.
Delayed Quote NYSE
| 28/08/2026 | 31/08/2026 | 01/09/2026 | 02/09/2026 | 03/09/2026 | |
|---|---|---|---|---|---|
| Last | US$2.540 | US$2.570 | US$2.590 | US$2.590 | US$2.620 |
| Volume | 490,228 | 748,350 | 598,262 | 454,863 | 931,918 |
| Change | -2.68% | +1.18% | +0.78% | 0.00% | +1.16% |
| Opening | US$2.610 | US$2.550 | US$2.610 | US$2.590 | US$2.590 |
| High | US$2.620 | US$2.610 | US$2.670 | US$2.640 | US$2.665 |
| Low | US$2.530 | US$2.525 | US$2.565 | US$2.585 | US$2.570 |
Performance
| 1 day | +1.16% | ||
| 1 week | +0.38% | ||
| Current month | +1.95% | ||
| 1 month | +12.93% | ||
| 3 months | +33.67% | ||
| 6 months | -7.42% | ||
| Current year | +45.56% | ||
| 1 year | +63.75% | ||
| 3 years | +32.32% | ||
| 5 years | +62.73% | ||
| 10 years | -56.33% |
Volumes
marketsDaily volume
942,012
Estimated daily volume
942,012
Avg. Volume 20 sessions
862,598
Daily volume ratio
1.09
Avg. Volume 20 sessions USD
2,260,006.76
Record volume 1
191,289,000
Record volume 2
19,414,390
Record volume 3
12,716,823
Capital turnover ratio
0.01
Float rotation
0.01
Basic data
Market Cap (USD)
208,680,552
Net sales (USD)
52,744,000
Number of employees
226
Sales / Employee (USD)
233,381
Free-Float
96.12 %
Free-Float capitalization (USD)
200,588,346
Average Daily Capital Traded
1.08%
Indicators
Moving average 5 days
2.58
Moving average 20 days
2.44
Moving average 50 days
2.376
Moving average 100 days
2.235
Price spread / (MMA5)
-1.53%
Price spread / (MMA20)
-6.89%
Price spread / (MMA50)
-9.31%
Price spread / (MMA100)
-14.69%
STIM
RSI 9 days
64.66
RSI 14 days
61.39
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.16% | +0.38% | +63.75% | +32.32% | 209M | |
| -0.04% | -1.40% | +57.16% | +108.15% | 1,034B | |
| +1.17% | +4.76% | +56.42% | +73.50% | 663B | |
| -0.58% | +0.80% | +22.82% | +75.58% | 462B | |
| +2.09% | -2.06% | +32.28% | +37.41% | 344B | |
| 0.00% | +5.36% | +27.40% | +46.97% | 307B | |
| +1.42% | +0.26% | -0.52% | +13.51% | 251B | |
| +0.29% | +1.63% | +56.46% | +73.00% | 239B | |
| -0.03% | +2.13% | -17.30% | -53.65% | 207B | |
| +1.08% | +1.59% | +33.83% | +97.29% | 186B | |
| Average | +0.60% | +0.75% | +33.23% | +50.41% | 369.36B | |
| Weighted average by Cap. | +0.33% | +0.40% | +38.63% | +67.86% |
Historical Quotes: Protalix BioTherapeutics, Inc.
| Date | Opening | High | Low | Close | Volume | Change |
|---|
Latest transactions
553.IjjVGtjd7i3ZacPqYdDERfECytIOSMsJ08be-pf5DYM.TF7jUontvlfvW7ewIrevcKQvm-JIHbpvmv_vrNnORftxW-V7vJ_cap8P8w
| Date | Price | Volume | Total |
|---|---|---|---|
| 21:00:00 | 2.620 | 42,290 | 838,920 |
| 20:59:59 | 2.615 | 300 | 796,630 |
| 20:59:59 | 2.610 | 500 | 796,330 |
| 20:59:59 | 2.610 | 800 | 795,830 |
| 20:59:59 | 2.610 | 100 | 795,030 |
| 20:59:59 | 2.615 | 600 | 794,930 |
| 20:59:57 | 2.620 | 100 | 794,330 |
| 20:59:56 | 2.615 | 100 | 794,230 |
| 20:59:56 | 2.615 | 100 | 794,130 |
| 20:59:55 | 2.615 | 100 | 794,030 |
Price Extremes
| 1 week | 2.52 |  | 2.67 |
| 1 month | 2.17 | | 2.7 |
| Current year | 1.72 | | 3.19 |
| 1 year | 1.52 | | 3.19 |
| 3 years | 0.82 | | 3.19 |
| 5 years | 0.7 | | 3.55 |
| 10 years | 0.7 | | 15.15 |
Monthly variations
Annual variations
| 2026 | +45.56% | ||
| 2025 | -4.26% | ||
| 2024 | +5.62% | ||
| 2023 | +29.93% | ||
| 2022 | +64.72% | ||
| 2021 | -77.09% | ||
| 2020 | +10.67% | ||
| 2019 | +5.47% | ||
| 2018 | -52.96% | ||
| 2017 | +48.58% | ||
| 2016 | -56.37% | ||
| 2015 | -44.57% | ||
| 2014 | -52.70% | ||
| 2013 | -25.05% | ||
| 2012 | +5.27% | ||
| 2011 | -50.60% | ||
| 2010 | +50.76% | ||
| 2009 | +259.78% | ||
| 2008 | -45.88% | ||
| 2007 | -87.48% |
- Stock Market
- Stocks
- PLX Stock
- Quotes Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
